Cristi Radford, MS, CGC, and Michele Gabree, MS, CGC, explain what variants of uncertain significance are, and address some of the questions that are frequently asked by providers.
The FDA granted accelerated approval to nivolumab based on a notable clinical benefit in a subset of patients who progressed after receiving the standard first-line chemotherapy with fluoropyrimidine, oxaliplatin, and irinotecan.
“Compared to those not enrolled in clinical trials, the evidence shows that the minority patients participating in clinical trials had increased overall survival,” said Khilen B. Patel, MD, at the 2018 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.
To sign up for our newsletter or print publications, please enter your contact information below.
